Enlivex Ltd.

Enlivex Ltd. is a longevity company developing therapies designed to extend healthspan and improve quality of life, combining a clinical pipeline focused on inflammatory aging-related conditions with a cryptocurrency-backed treasury strategy. The company's primary therapeutic candidate, Allocetra™, is a macrophage reprogramming therapy targeting osteoarthritis and other inflammatory disorders; it is manufactured at a cGMP facility in Israel and being evaluated in clinical trials with plans for commercialization through partnership agreements. The company also operates a digital asset treasury anchored in decentralized prediction markets infrastructure through the RAIN protocol, which it intends to employ for capital appreciation and to support its clinical development and operational needs.